Genetic variants of the beta-adrenergic receptor pathways as both risk and protective factors for retinopathy of prematurity. American Journal Of Ophthalmology. 10.1016/j.ajo.2023.12.017 (Original work published 2024)
. (2024). Robert Gendron
CD10+ Cells and IgM in Pathogen Response in Lumpfish (Cyclopterus lumpus) Eye Tissues. Frontiers In Immunology, 11, 576897. 10.3389/fimmu.2020.576897 (Original work published 2020)
. (2020). Tubedown regulation of retinal endothelial permeability signaling pathways. Biology Open, 4(8), 970-9. 10.1242/bio.010496 (Original work published 2015)
. (2015). Loss of tubedown expression as a contributing factor in the development of age-related retinopathy. Investigative Ophthalmology & Visual Science, 51(10), 5267-77. 10.1167/iovs.09-4527 (Original work published 2010)
. (2010). Genomics and proteomics of retinopathy of prematurity: DNA-based prevention and treatment. The British Journal Of Ophthalmology, 91(12), 1577. 10.1136/bjo.2007.124404 (Original work published 2007)
. (2007). Retinopathy of prematurity: gone today, here tomorrow?. Clinical & Experimental Ophthalmology, 33(4), 339-40. 10.1111/j.1442-9071.2005.01057.x (Original work published 2005)
. (2005). Tubedown-1 (Tbdn-1) suppression in oxygen-induced retinopathy and in retinopathy of prematurity. Molecular Vision, 12, 108-16. Retrieved de http://www.molvis.org/molvis/v12/a12/ (Original work published 2006)
. (2006). Retinopathy of prematurity's turning point. The British Journal Of Ophthalmology, 89(2), 127-8. 10.1136/bjo.2004.058560 (Original work published 2005)
. (2005). Conditional knockdown of tubedown-1 in endothelial cells leads to neovascular retinopathy. Investigative Ophthalmology & Visual Science, 45(10), 3704-12. 10.1167/iovs.03-1410 (Original work published 2004)
. (2004). Retinopathy of prematurity. Ophthalmology Clinics Of North America, 14(3), 513-9. 10.1016/s0896-1549(05)70249-2 (Original work published 2001)
. (2001).